NASDAQ: CDTXCidara Therapeutics Inc Stock
$21.54+0.06 (+0.28%)
Updated Apr 25, 2025
CDTX Price
$21.54
Fair Value Price
$26.33
Market Cap
$235.94M
52 Week Low
$10.14
52 Week High
$28.42
P/E
-0.81x
P/B
1.44x
P/S
133.87x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.28M
Earnings
-$169.83M
Gross Margin
100%
Operating Margin
-13,319.76%
Profit Margin
-13,319.8%
Debt to Equity
0.32
Operating Cash Flow
-$177M
Beta
0.7
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CDTX Overview
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CDTX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CDTX
Ranked#406 of 460
Ranked#406 of 460
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.85 | A | |
| $8.18 | A | |
| $23.45 | A |
Be the first to know about important CDTX news, forecast changes, insider trades & much more!
CDTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CDTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CDTX ($21.54) is undervalued by 18.18% relative to our estimate of its Fair Value price of $26.33 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CDTX ($21.54) is not significantly undervalued (18.18%) relative to our estimate of its Fair Value price of $26.33 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CDTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CDTX due diligence checks available for Premium users.
Valuation
CDTX fair value
Fair Value of CDTX stock based on Discounted Cash Flow (DCF)
Price
$21.54
Fair Value
$26.33
Undervalued by
18.18%
CDTX ($21.54) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CDTX ($21.54) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CDTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CDTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.81x
Industry
-157.91x
Market
29.65x
CDTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.44x
Industry
4.26x
CDTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CDTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$52.3M
Profit Margin
0%
CDTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CDTX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$214.8M
Liabilities
$51.5M
Debt to equity
0.32
CDTX's short-term assets ($210.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CDTX's short-term assets ($210.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CDTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CDTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$29.4M
Investing
$0.0
Financing
$98.2M
CDTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CDTX vs Biotech Stocks
Cidara Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.